Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2009 Financial Results on July 23, 2009

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc.
(Nasdaq: SGEN) announced today that it will report its second
quarter 2009 financial results on Thursday, July 23, 2009, after
the close of financial markets. Following the announcement, company
management will host a conference call and webcast discussion of
the results and provide a general corporate update. Access to the
event can be obtained as follows:

Telephone replay will be available beginning at approximately
4:00 p.m. PT on July 23, 2009 through 4:00 p.m. PT on July 27, 2009
by calling (800) 406-7325 (domestic) or (303) 590-3030
(international); conference ID 4114066
Webcast replay will be available on the Seattle Genetics website at
www.seattlegenetics.com in the
News and Investor Information section
About Seattle Genetics

Seattle Genetics is a clinical stage biotechnology company
focused on the development and commercialization of monoclonal
antibody-based therapies for the treatment of cancer and autoimmune
disease. The company’s lead product candidate, SGN-35, is in
a pivotal trial under a special protocol assessment with the FDA.
SGN-35 is empowered by Seattle Genetics’ proprietary
antibody-drug conjugate (ADC) technology comprising highly potent
synthetic drugs and stable linkers for attaching the drugs to
monoclonal antibodies. In addition, Seattle Genetics has three
other product candidates in ongoing clinical trials: dacetuzumab
(SGN-40), lintuzumab (SGN-33) and SGN-70. Dacetuzumab is being
developed under a worldwide collaboration with Genentech (a
wholly-owned member of the Roche Group). Seattle Genetics has
collaborations for its ADC technology with a number of leading
biotechnology and pharmaceutical companies, including Genentech,
Bayer, CuraGen, Progenics, Daiichi Sankyo, MedImmune, a subsidiary
of AstraZeneca, and Millennium: The Takeda Oncology Company, as
well as an ADC co-development agreement with Agensys, a subsidiary
of Astellas Pharma. More information can be found at www.seattlegenetics.com.